Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
To the Editor.— The Thai Ministry of Health and the US Centers for Disease Control and Prevention recently released preliminary results from their trial demonstrating a 51% reduction of mother-to-child transmission associated with short-course zidovudine given from 36 weeks' gestation through labor.1 Using this zidovudine efficacy estimate adjusted for a breast-feeding population, updated information on a range of counseling and testing costs,2,3 prenatal maternal testing rates (Bernard Nahlen, MD, oral communication, April 1998), and reductions in zidovudine cost (announced by Glaxo Wellcome, Inc4), we reevaluated our analysis3 of the cost-effectiveness of short-course zidovudine for prevention of mother-to-child human immunodeficiency virus (HIV) transmission for sub-Saharan African countries with the greatest burden of HIV in childbearing women and infants (eg, Ivory Coast, Tanzania, Uganda).
Mansergh G, Haddix AC, Steketee RW, Simonds RJ. Cost-effectiveness of Zidovudine to Prevent Mother-to-Child Transmission of HIV in Sub-Saharan Africa. JAMA. 1998;280(1):30-31. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-1-jbk0701